Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 3 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Gwo Xi Stem Cell Applied Technology Co. Ltd. has 6 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 6 examiners and 3 art units, showing distinct examiner handling within a smaller set of examination groups.
MATALKAH, FATIMAH KHALAF is the busiest examiner, with 1 pending action. The workload is distributed across the other examiner assignments, so counsel should manage each response separately while coordinating technical positions within the three art units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §103 only | 1 (17%) |
| §112 only | 1 (17%) |
| Multi-statute (no §101) | 3 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MATALKAH, FATIMAH KHALAF | 1 | 55.8% | +27.4% |
| JOHNSON, KARA D | 1 | 69.3% | +25.1% |
| BEHARRY, ZANNA MARIA | 1 | 25.0% | +56.3% |
| ABEYRATNE-PERERA, HASHANTHI KOMITIGE | 1 | 0.0% | +0.0% |
| BRAUN, MADELINE E | 1 | 68.4% | +25.3% |
| THUESON, HANNA MARIE | 1 | 76.7% | +28.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18126273 | METHOD FOR TREATING DEMYELINATING CONDITIONS | BRAUN, MADELINE E | 157d overdue |
| 19012977 | PREPARATION METHOD OF PHARMACEUTICAL COMPOSITION FOR TREATING CHRONIC STROKE | MATALKAH, FATIMAH KHALAF | — |
| 18964649 | HIGH SECRETION INSULIN-PRODUCING CELLS | JOHNSON, KARA D | — |
| 18525926 | PHARMACEUTICAL COMPOSITION COMPRISING ADIPOSE TISSUE-DERIVED EXTRACELLULAR VESICLE AND BIOLOGIC AND USE OF PHARMACEUTICAL COMPOSITION FOR TREATING ARTHRITIS | BEHARRY, ZANNA MARIA | — |
| 18376440 | MODIFIED STEM CELL AND PREPARATION METHOD AND USE THEREOF | ABEYRATNE-PERERA, HASHANTHI KOMITIGE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18126273 | METHOD FOR TREATING DEMYELINATING CONDITIONS | BRAUN, MADELINE E | 157d overdue |
| 18066999 | METHOD FOR STABLY AMPLIFYING PLURIPOTENT STEM CELL | THUESON, HANNA MARIE | 49d overdue |
| 19012977 | PREPARATION METHOD OF PHARMACEUTICAL COMPOSITION FOR TREATING CHRONIC STROKE | MATALKAH, FATIMAH KHALAF | — |
| 18964649 | HIGH SECRETION INSULIN-PRODUCING CELLS | JOHNSON, KARA D | — |
| 18525926 | PHARMACEUTICAL COMPOSITION COMPRISING ADIPOSE TISSUE-DERIVED EXTRACELLULAR VESICLE AND BIOLOGIC AND USE OF PHARMACEUTICAL COMPOSITION FOR TREATING ARTHRITIS | BEHARRY, ZANNA MARIA | — |
| Art Unit | Apps |
|---|---|
| 1632 | 3 |
| 1638 | 2 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19012977 | PREPARATION METHOD OF PHARMACEUTICAL COMPOSITION FOR TREATING CHRONIC STROKE | MATALKAH, FATIMAH KHALAF | 1638 | §103§112 | Non-Final OA | — | Pending | Jan 08, 2025 |
| 18964649 | HIGH SECRETION INSULIN-PRODUCING CELLS | JOHNSON, KARA D | 1632 | §102§112 | Non-Final OA | — | Pending | Dec 01, 2024 |
| 18525926 | PHARMACEUTICAL COMPOSITION COMPRISING ADIPOSE TISSUE-DERIVED EXTRACELLULAR VESICLE AND BIOLOGIC AND USE OF PHARMACEUTICAL COMPOSITION FOR TREATING ARTHRITIS | BEHARRY, ZANNA MARIA | 1632 | §101§102§103DP | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18376440 | MODIFIED STEM CELL AND PREPARATION METHOD AND USE THEREOF | ABEYRATNE-PERERA, HASHANTHI KOMITIGE | 1632 | §112Other | Final Rejection | — | Pending | Oct 03, 2023 |
| 18126273 | METHOD FOR TREATING DEMYELINATING CONDITIONS | BRAUN, MADELINE E | 1624 | §103§112 | Final Rejection | 157d overdue | Pending | Mar 24, 2023 |
| 18066999 | METHOD FOR STABLY AMPLIFYING PLURIPOTENT STEM CELL | THUESON, HANNA MARIE | 1638 | §103 | Non-Final OA | 49d overdue | Pending | Dec 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGwo Xi Stem Cell Applied Technology Co. Ltd. has 6 pending office actions as of October 2026, spread across 3 art units and 6 examiners.
Fatimah Khalaf Matalkah has the most, with 1 of Gwo Xi Stem Cell Applied Technology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
